As most obvious hit, treatment strongly reduced tumor load in all 3 samples bearing BCL2-sgRNAs, indicating that knockout of BCL2 restored sensitivity of resistant PDX ALL-199 cells towards treatment in vivo. Here, BCL2 is linked to acute lymphoblastic leukemia.